TY - JOUR
T1 - Protein scaffolds in human clinics
AU - Cano-Garrido, Olivia
AU - Serna, Naroa
AU - Unzueta, Ugutz
AU - Parladé, Eloi
AU - Mangues, Ramón
AU - Villaverde, Antonio
AU - Vázquez, Esther
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/12
Y1 - 2022/12
N2 - Fundamental clinical areas such as drug delivery and regenerative medicine require biocompatible materials as mechanically stable scaffolds or as nanoscale drug carriers. Among the wide set of emerging biomaterials, polypeptides offer enticing properties over alternative polymers, including full biocompatibility, biodegradability, precise interactivity, structural stability and conformational and functional versatility, all of them tunable by conventional protein engineering. However, proteins from non-human sources elicit immunotoxicities that might bottleneck further development and narrow their clinical applicability. In this context, selecting human proteins or developing humanized protein versions as building blocks is a strict demand to design non-immunogenic protein materials. We review here the expanding catalogue of human or humanized proteins tailored to execute different levels of scaffolding functions and how they can be engineered as self-assembling materials in form of oligomers, polymers or complex networks. In particular, we emphasize those that are under clinical development, revising their fields of applicability and how they have been adapted to offer, apart from mere mechanical support, highly refined functions and precise molecular interactions.
AB - Fundamental clinical areas such as drug delivery and regenerative medicine require biocompatible materials as mechanically stable scaffolds or as nanoscale drug carriers. Among the wide set of emerging biomaterials, polypeptides offer enticing properties over alternative polymers, including full biocompatibility, biodegradability, precise interactivity, structural stability and conformational and functional versatility, all of them tunable by conventional protein engineering. However, proteins from non-human sources elicit immunotoxicities that might bottleneck further development and narrow their clinical applicability. In this context, selecting human proteins or developing humanized protein versions as building blocks is a strict demand to design non-immunogenic protein materials. We review here the expanding catalogue of human or humanized proteins tailored to execute different levels of scaffolding functions and how they can be engineered as self-assembling materials in form of oligomers, polymers or complex networks. In particular, we emphasize those that are under clinical development, revising their fields of applicability and how they have been adapted to offer, apart from mere mechanical support, highly refined functions and precise molecular interactions.
KW - drug delivery
KW - human protein
KW - humanization
KW - nanomedicine
KW - Protein materials
KW - regenerative medicine, self-assembling
UR - http://www.scopus.com/inward/record.url?scp=85139218185&partnerID=8YFLogxK
U2 - 10.1016/j.biotechadv.2022.108032
DO - 10.1016/j.biotechadv.2022.108032
M3 - Review article
C2 - 36089254
AN - SCOPUS:85139218185
SN - 0734-9750
VL - 61
JO - Biotechnology Advances
JF - Biotechnology Advances
M1 - 108032
ER -